Literature DB >> 23244718

Interleukin-27: balancing protective and pathological immunity.

Christopher A Hunter1, Rob Kastelein.   

Abstract

It has been more than 15 years since the identification of individual interleukin-27 (IL-27) and IL-27 receptor components. The last decade has seen the description of the signaling pathways engaged by IL-27, and an appreciation has emerged that this cytokine can modulate the intensity and duration of many classes of T cell responses. Here we provide an overview of the immunobiology of IL-27 and review advances in understanding the functions of individual IL-27 and IL-27 receptor subunits and the role of IL-27 in dictating the balance between protective and pathological immunity. Additionally, this cytokine has been proposed as a therapy to modify inflammatory conditions or to promote antitumor responses, and situations where experimental and clinical data sets implicate IL-27 in the outcome of disease are highlighted.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23244718      PMCID: PMC3531794          DOI: 10.1016/j.immuni.2012.11.003

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  127 in total

Review 1.  Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation.

Authors:  Robert A Kastelein; Christopher A Hunter; Daniel J Cua
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

2.  IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1.

Authors:  Clemens Neufert; Christoph Becker; Stefan Wirtz; Massimo C Fantini; Benno Weigmann; Peter R Galle; Markus F Neurath
Journal:  Eur J Immunol       Date:  2007-07       Impact factor: 5.532

3.  Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system.

Authors:  Jason S Stumhofer; Arian Laurence; Emma H Wilson; Elaine Huang; Cristina M Tato; Leanne M Johnson; Alejandro V Villarino; Qiulong Huang; Akihiko Yoshimura; David Sehy; Christiaan J M Saris; John J O'Shea; Lothar Hennighausen; Matthias Ernst; Christopher A Hunter
Journal:  Nat Immunol       Date:  2006-08-13       Impact factor: 25.606

4.  Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells.

Authors:  Marcel Batten; Ji Li; Sothy Yi; Noelyn M Kljavin; Dimitry M Danilenko; Sophie Lucas; James Lee; Frederic J de Sauvage; Nico Ghilardi
Journal:  Nat Immunol       Date:  2006-08-13       Impact factor: 25.606

5.  IL-27 induces the production of IgG1 by human B cells.

Authors:  Amel Boumendjel; Lina Tawk; René de Waal Malefijt; Vera Boulay; Hans Yssel; Jérôme Pène
Journal:  Eur Cytokine Netw       Date:  2006-12       Impact factor: 2.737

6.  Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population.

Authors:  Soo-Cheon Chae; Chun-Shi Li; Ki Mo Kim; Ji Yeon Yang; Qinggao Zhang; Yong-Chul Lee; Yun-Sik Yang; Hun-Taeg Chung
Journal:  J Hum Genet       Date:  2007-02-22       Impact factor: 3.172

7.  TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1.

Authors:  Ahjoku Amadi-Obi; Cheng-Rong Yu; Xuebin Liu; Rashid M Mahdi; Grace Levy Clarke; Robert B Nussenblatt; Igal Gery; Yun Sang Lee; Charles E Egwuagu
Journal:  Nat Med       Date:  2007-05-13       Impact factor: 53.440

8.  Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate.

Authors:  Jia-Jun Liao; Mei-Chuan Huang; Edward J Goetzl
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

9.  IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3.

Authors:  Céline Molle; Muriel Nguyen; Véronique Flamand; Joelle Renneson; François Trottein; Dominique De Wit; Fabienne Willems; Michel Goldman; Stanislas Goriely
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

Review 10.  The biology and therapeutic potential of interleukin 27.

Authors:  Marcel Batten; Nico Ghilardi
Journal:  J Mol Med (Berl)       Date:  2007-02-10       Impact factor: 5.606

View more
  117 in total

1.  IL-27 signaling deficiency develops Th17-enhanced Th2-dominant inflammation in murine allergic conjunctivitis model.

Authors:  Xin Chen; Ruzhi Deng; Wei Chi; Xia Hua; Fan Lu; Fang Bian; Ning Gao; Zhijie Li; Stephen C Pflugfelder; Cintia S de Paiva; De-Quan Li
Journal:  Allergy       Date:  2019-01-04       Impact factor: 13.146

Review 2.  Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

Authors:  Michel DuPage; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2016-02-15       Impact factor: 53.106

3.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

Review 4.  Modeling the T cell immune response: a fascinating challenge.

Authors:  Penelope A Morel; James R Faeder; William F Hawse; Natasa Miskov-Zivanov
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-26       Impact factor: 2.745

5.  Engineering a potent receptor superagonist or antagonist from a novel IL-6 family cytokine ligand.

Authors:  Jun W Kim; Cesar P Marquez; R Andres Parra Sperberg; Jiaxiang Wu; Won G Bae; Po-Ssu Huang; E Alejandro Sweet-Cordero; Jennifer R Cochran
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-10       Impact factor: 11.205

6.  Double-Negative αβ T Cells Are Early Responders to AKI and Are Found in Human Kidney.

Authors:  Maria N Martina; Sanjeev Noel; Ankit Saxena; Samatha Bandapalle; Richa Majithia; Chunfa Jie; Lois J Arend; Mohamad E Allaf; Hamid Rabb; Abdel Rahim A Hamad
Journal:  J Am Soc Nephrol       Date:  2015-08-27       Impact factor: 10.121

Review 7.  Interleukin 35: Critical regulator of immunity and lymphocyte-mediated diseases.

Authors:  Charles E Egwuagu; Cheng-Rong Yu; Lin Sun; Renxi Wang
Journal:  Cytokine Growth Factor Rev       Date:  2015-07-20       Impact factor: 7.638

8.  Interleukin-27 enhances TNF-α-mediated activation of human coronary artery endothelial cells.

Authors:  Huai-Na Qiu; Bin Liu; Weihua Liu; Shiming Liu
Journal:  Mol Cell Biochem       Date:  2015-09-19       Impact factor: 3.396

9.  Impact of Interleukin-27p28 on T and B Cell Responses during Toxoplasmosis.

Authors:  Jeongho Park; Jonathan H DeLong; James J Knox; Christoph Konradt; Elia D Tait Wojno; Christopher A Hunter
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

10.  The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

Authors:  Sènan M d'Almeida; Gilles Kauffenstein; Charlotte Roy; Laetitia Basset; Loukas Papargyris; Daniel Henrion; Véronique Catros; Norbert Ifrah; Philippe Descamps; Anne Croue; Pascale Jeannin; Marc Grégoire; Yves Delneste; Julie Tabiasco
Journal:  Oncoimmunology       Date:  2016-04-28       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.